ACTIVE NON-SEGMENTAL VITILIGO

Clinical trials for ACTIVE NON-SEGMENTAL VITILIGO explained in plain language.

Never miss a new study

Get alerted when new ACTIVE NON-SEGMENTAL VITILIGO trials appear

Sign up with your email to follow new studies for ACTIVE NON-SEGMENTAL VITILIGO, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug IBI3013 targets skin conditions in early trial

Disease control Recruiting now

This early-stage study tests a new drug called IBI3013 in healthy people and those with active vitiligo or severe alopecia areata. The goal is to check if the drug is safe and how the body processes it. The study involves up to 160 participants and lasts up to 48 weeks for those …

Matched conditions: ACTIVE NON-SEGMENTAL VITILIGO

Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control

Last updated May 08, 2026 12:03 UTC

ACTIVE NON-SEGMENTAL VITILIGO

Get alerted when new ACTIVE NON-SEGMENTAL VITILIGO trials appear

New drug IBI3013 targets skin conditions in early trial